
|Videos|October 13, 2017
What is the Advantage of Administering a Beta-Lactam with a Beta-Lactamase Inhibitor?
Author(s)Contagion® Editorial Staff
Amanda Paschke, MD, MSCE, explains the advantage of administering a beta-lactam in combination with a beta-lactamase inhibitor.
Advertisement
Amanda Paschke, MD, MSCE, director of Clinical Research, Infectious Diseases, at Merck, breaks down the advantages of administering a beta-lactam in combination with a beta-lactamase inhibitor. Dr. Paschke highlights Merck’s development compound imipenem-relebactam, and explains how relebactam restores susceptibility to imipenem.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Top Infectious Disease News Stories Week of November 29 - December 5
2
Early 2025 Influenza Vaccination Trends Following Prior Season and H3N2 Start
3
ACIP Votes on Hepatitis B Vaccine Marks More Confusion, No Supportive Safety Data, and Uncertainty of Public Health Policy
4
Call to Consider Off-Label COVID-19 Vaccination for Children
5

















































































































































































































































































